{{Drugbox
| Verifiedfields =
| verifiedrevid =
| IUPAC_name = 1-pentyfluoro-1''H''-indole-3-carboxylic acid 8-quinolinyl ester
| image = 5F-PB-22.png
| width = 200

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| excretion =
| legal_CA = Schedule II
| legal_US = Schedule I
| legal_UK= Class B
| legal_DE = Anlage II<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 1400742-41-7
| ATC_prefix =
| ATC_suffix =
| PubChem =
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID      = 29341631
| smiles            = C1=CC=C2C(=C1)C(=CN2CCCCCF)C(=O)OC3=CC=CC4=C3N=CC=C4
| StdInChI          = 1S/C23H21FN2O2/c24-13-4-1-5-15-26-16-19(18-10-2-3-11-20(18)26)23(27)28-21-12-6-8-17-9-7-14-25-22(17)21/h2-3,6-12,14,16H,1,4-5,13,15H2
| StdInChIKey       = MBOCMBFDYVSGLJ-UHFFFAOYSA-N

<!--Chemical data-->
| C=23 | H=21 | F=1 | N=2 | O=2
| molecular_weight = 376.42 g/mol
|drug_name=|alt=|caption=|type=|MedlinePlus=|legal_status=|licence_EU=|pregnancy_category=|licence_US=}}

'''5F-PB-22''' ('''5F-QUPIC''' or '''Quinolin-8-yl 1-pentyfluoro-1''H''-indole-3-8-carboxylate''') is a [[designer drug]] which acts as a [[cannabinoid agonist]].<ref>{{Cite journal | doi = 10.1021/acschemneuro.5b00107| title = Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135| journal = ACS Chemical Neuroscience| volume = 6| issue = 8| pages = 150508124201002| year = 2015| last1 = Banister | first1 = S. D. | last2 = Stuart | first2 = J. | last3 = Kevin | first3 = R. C. | last4 = Edington | first4 = A. | last5 = Longworth | first5 = M. | last6 = Wilkinson | first6 = S. M. | last7 = Beinat | first7 = C. | last8 = Buchanan | first8 = A. S. | last9 = Hibbs | first9 = D. E. | last10 = Glass | first10 = M. | last11 = Connor | first11 = M. | last12 = McGregor | first12 = I. S. | last13 = Kassiou | first13 = M. | pmid=25921407}}</ref> The structure of 5F-PB-22 appears to have been designed with an understanding of [[structure-activity relationship]]s within the indole class of cannabinoids.<ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1233 | title=5F-PB-22 | publisher=Forendex | accessdate=24 June 2015}}</ref>

==Pharmacology==
5F-PB-22 acts as a [[full agonist]] with a [[Affinity (pharmacology)#Protein-ligand binding|binding affinity]] of 0.468nM at [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and 0.633nM at [[Cannabinoid receptor type 2|CB<sub>2</sub>]] [[cannabinoid]] receptors.<ref>{{cite journal|first1=Cornelius|last1=Hess|first2=ClaraT.|last2=Schoeder|first3=Thanigaimalai|last3=Pillaiyar|first4=Burkhard|last4=Madea|title=Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice|journal=Forensic Toxicology|date=1 July 2016|issn=1860-8965|pages=329–343|volume=34|issue=2|doi=10.1007/s11419-016-0320-2|first5=ChristaE.|last5=Müller|pmid=27429655|pmc=4929166}}</ref>

==Legal Status==

As of October 2015 5F-PB-22 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

In January 2014, 5F-PB-22 was designated as a [[Schedule I controlled substance]] in the United States after several deaths were associated with its use.<ref name=pmid24876364>{{Cite journal
 | pmid = 24876364
| pmc = 4334789
| year = 2014
| author1 = Behonick
| first1 = G
| title = Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22
| journal = Journal of analytical toxicology
| last2 = Shanks
| first2 = K. G.
| last3 = Firchau
| first3 = D. J.
| last4 = Mathur
| first4 = G
| last5 = Lynch
| first5 = C. F.
| last6 = Nashelsky
| first6 = M
| last7 = Jaskierny
| first7 = D. J.
| last8 = Meroueh
| first8 = C
| doi = 10.1093/jat/bku048
 | volume=38
 | issue = 8
| pages=559–62
}}</ref><ref>{{cite journal | url=http://www.nejm.org/doi/full/10.1056/NEJMp1505328 | title=Synthetic Cannabinoid–Related Illnesses and Deaths |author1=Jordan Trecki |author2=Roy R. Gerona |author3=Michael D. Schwartz | journal=New England Journal of Medicine |date=July 2015  | volume=373 | issue=2 | pages=103–107 | doi=10.1056/NEJMp1505328 | pmid=26154784}}</ref>

In the United Kingdom (as of May 2016), previously unregulated substances deemed to be psychoactive are now controlled by the Psychoactive Substances Act. Consequently, the sale, distribution, import, and purchase of 5F-PB-22 is banned.<ref>{{Cite web|url=http://services.parliament.uk/bills/2015-16/psychoactivesubstances.html|title=Psychoactive Substances Act 2016 — UK Parliament|website=services.parliament.uk|access-date=2016-11-02}}</ref> 

==See also==
* [[AM-2201]]
* [[JWH-018]]
* [[QUCHIC]]
* [[QUPIC]]
* [[SDB-001]]
* [[SDB-005]]

==References==
{{reflist}}

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indoles]]
[[Category:Fluoroalkanes]]


{{cannabinoid-stub}}